PLX-51107 is under clinical development by Plexxikon and currently in Phase I for Myeloproliferative Disorders. According to GlobalData, Phase I drugs for Myeloproliferative Disorders have an 83% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how PLX-51107’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PLX-51107 is under development for the treatment of chronic lymphocytic leukemia, acute myeloid leukemia, high-risk myelodysplastic syndrome (MDS) and myeloproliferative neoplasm. The drug candidate is a small molecule which acts by targeting BRD4. It is administered through oral route and parenteral route. It was also under development for the treatment of advanced malignancies, solid tumors, lymphoma, relapsed or refractory acute myeloid leukemia, high-risk myelodysplastic syndrome (MDS).
Plexxikon, a subsidiary of Daiichi Sankyo Co Ltd, carries out the discovery and development of novel small molecule therapeutics to treat cancers. Its pipeline products portfolio includes pexidartinib indicated for the treatment of adjuvant glioblastoma, neoadjuvant breast, melanoma, and solid tumors; PLX7486 to treat pancreatic and solid tumors; PLX 9486 to treat the gastrointestinal stromal tumor and KIT-Mutant tumors; and PLX8394 to treat BRAF-Mutant tumors; PLX51107 against solid tumors, hematologic malignancies; PLX73086 addressing solid tumors. It conducts clinical trials to evaluate a novel drug or combination of drugs or the new use of a marketed drug. The company conducts research in collaboration with academic and clinical researchers to develop new drug therapies. Plexxikon is headquartered in South San Francisco, California, the US.
For a complete picture of PLX-51107’s drug-specific PTSR and LoA scores, buy the report here.